Multi-cancer early detection (MCED)
Multi-cancer early detection (MCED) screens asymptomatic, average-risk individuals from a single blood draw for molecular signals shared across dozens of cancer types — a population-screening scenario distinct from companion-therapy diagnostics.
How it works
This is a procurement category, not a named manufacturer's product. As a paid service, Bioecon finds suppliers for your task, agrees configuration and specification, and arranges supply; the price is on request. Bioecon may receive a fee from suppliers — this is disclosed and does not affect the portal's grades or lists.
Technology
Multi-cancer early detection (MCED) — Evidence, registration route, funding and suppliers are on the technology page.
A single blood draw screening asymptomatic, average-risk individuals for signals of dozens of cancer types simultaneously, aiming to catch cancer before symptoms appear — distinct from treatment-matched companion diagnostics: GRAIL's Galleri (US), Exact Sciences' Cancerguard (US) and Freenome (US), …
Links
- Import and registration route
- SERV — — (operator: Rosprirodnadzor, Rostechnadzor)
- Capabilities
- Testing & analytics
Related items
Other categories for this technology
Laboratory & analytical instruments · Reagents & kits
In the same node
Allelopathic crops · Aquaculture microbiome management · Automated ELISA analyzers · BECCS · Bio-content certification & mass-balance traceability (ISCC PLUS, USDA BioPreferred) · Bio-flotation reagents for mining · Bio-integrated DAC (hybrid bio-DAC) · Bio-mining (phytoremediation, tailings valorization) · All →